Decreased serum levels of il-27and il-35 in patients with graves disease

Saeed, M.-H. and Kurosh, K. and Zahra, A. and Hossein, D.M. and Davood, R. and Ataollahi, M.R. (2020) Decreased serum levels of il-27and il-35 in patients with graves disease. Archives of Endocrinology and Metabolism.

Full text not available from this repository.
Official URL:


Objectives: Graves� disease (GD) is an autoimmune disease causing the overproduction of the thyroid hormone from thyroid gland. This disease is mainly the result of the production of antibodies against TSH receptors. Cytokines play an important role in orchestrating the pathophysiology in autoimmune thyroid disease. The regulatory role of IL-12 on TH1 cells has been proven. IL-27 and IL-35, members of IL-12 cytokine family, are two cytokines that have been newly discovered. IL-35 has been identified as a novel immunosuppressive and anti-inflammatory cytokine while IL-27 has both inflammatory and anti-inflammatory functions. The objective of the current study was to examine the changes in the serum level of the foregoing cytokines in GD patients in comparison to healthy controls. Materials and methods: In this study, serum levels of IL-27 and IL-35 were determined by an ELISA method; anti TPO and anti Tg were measured by an RIA method in 40 new cases of Graves�s disease. The findings were compared with 40 healthy controls. Results: The results showed a significant difference between IL-27 and IL-35 regarding their serum levels with P values of 0.0001 and 0.024, respectively; anti TPO and anti Tg levels of the cases were also significantly different from controls (p < 0.001). Conclusion: The reduction in the serum levels of IL-27 and IL-35 in GD patients compared to normal subjects suggests the possible anti-inflammatory role of these cytokines in GD. Arch Endocrinol Metab. 2020;64(5):521-7. © 2020, Sociedade Brasileira de Endocrinologia e Metabologia. All rights reserved.

Item Type: Article
Depositing User: Unnamed user with email
Date Deposited: 07 Nov 2020 07:33
Last Modified: 07 Nov 2020 07:33

Actions (login required)

View Item View Item